Tenaya Therapeutics (TNYA) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Tenaya Therapeutics is expected to report Q2 2025 earnings on August 14, with analysts forecasting a loss of ($0.17) per share.
• The company's stock has a market capitalization of $109.74 million and institutional investors own approximately 90.54% of its shares.
• Analysts maintain a consensus rating of "Buy" for Tenaya Therapeutics, with price targets ranging from $5.00 to $9.00 per share.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect Tenaya Therapeutics to post earnings of ($0.17) per share for the quarter.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.06. On average, analysts expect Tenaya Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tenaya Therapeutics Stock Performance

Shares of NASDAQ:TNYA traded up $0.01 during trading hours on Friday, hitting $0.67. 1,244,207 shares of the company's stock traded hands, compared to its average volume of 2,764,692. The company has a market cap of $108.81 million, a price-to-earnings ratio of -0.70 and a beta of 3.01. Tenaya Therapeutics has a 52 week low of $0.36 and a 52 week high of $4.01. The company's fifty day simple moving average is $0.66 and its two-hundred day simple moving average is $0.68.

Institutional Trading of Tenaya Therapeutics

Several large investors have recently added to or reduced their stakes in TNYA. Woodline Partners LP raised its position in Tenaya Therapeutics by 30,563.2% in the 1st quarter. Woodline Partners LP now owns 5,916,167 shares of the company's stock valued at $3,373,000 after purchasing an additional 5,896,873 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of Tenaya Therapeutics during the first quarter worth approximately $442,000. Finally, Comerica Bank acquired a new position in shares of Tenaya Therapeutics in the 1st quarter valued at $50,000. 90.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on TNYA shares. Chardan Capital reiterated a "buy" rating and issued a $9.00 price target on shares of Tenaya Therapeutics in a research report on Thursday. HC Wainwright restated a "buy" rating and issued a $5.00 price objective on shares of Tenaya Therapeutics in a research note on Friday, April 25th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tenaya Therapeutics has a consensus rating of "Buy" and a consensus target price of $6.25.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.